to delays at the time of the survey in the drug\'s approval by the South African Medicines Control Council that have since been resolved.

###### 

Levels of access to commonly used second-line antiretroviral drugs in TREAT Asia and IeDEA Southern Africa

                             Categories of drug access                                                        and T Suwanlerk, The Netherlands, Australia, Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand;

K Chokephaibulkit\* and O Wittawatmongkol, Siriraj Hospital, Mahidol University;

HK Truong\* and DAN Mai, Children\'s Hospital 1, Ho Chi Minh City, Vietnam;

CV Do\* and MT Ha, Children\'s Hospital 2, Ho Chi Minh City, Vietnam;

HV Bui \*and VL Nguyen, National Hospital of Pediatrics, Hanoi, Vietnam;

ON Le, Worldwide Orphans Foundation, Ho Chi Minh City, Vietnam;

AH Sohn\*, L Messerschmidt and J Pang, TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand;

DA Cooper, MG Law\* and A Kariminia, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia;

\*TApHOD Steering Committee member

† Current Steering Committee Chair; ‡ co-Chair

IeDEA Southern Africa Paediatric Group

Mary-Ann Davies, School of Public Health and Family Medicine, University of Cape Town, South